Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Maximuscle powers Vodafone McLaren Mercedes drivers through the 2012 Formula 1™ season
Leading sports nutrition brand continues its presence with on-car logos in Hungary
-
Results announcement for the second quarter 2012
GSK delivers Q2 core EPS of 26.4p and dividend of 17p
-
GSK pre-broadcast statement on BBC Panorama: “The truth about Sports Products”, 19 July 2012
GSK issued statement in anticipation of BBC Panorama programme. The truth about sports products, scheduled to be aired this evening.
-
GlaxoSmithKline and Amicus Therapeutics expand Fabry disease collaboration
GSK & FOLD announced an expansion of their collaboration to develop the investigational pharmacological migalastat HCl for Fabry disease.
-
GlaxoSmithKline celebrates its role in supporting the biggest anti-doping operation in the history of the Olympic Games
GSK, Official Laboratory Services Provider for the London 2012 Olympic and Paralympic Games celebrating with anti-doping science campaign.
-
GSK to acquire Human Genome Sciences for US$14.25 per share in cash
GSK & HGS announced they have entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash.
-
US Regulatory Update – Tykerb® (lapatinib)
GSK announced it has withdrawn a sNDA to the FDA for lapatinib with trastuzumab for HER2 (ErbB2)-positive metastatic breast cancer
-
Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV
Shionogi-ViiV announced results received from Phase III SINGLE study of dolutegravir in treatment-naive adults with HIV-1.
-
GSK announces positive data from Harmony 8 and completion of clinical registration package for albiglutide in type 2 diabetes
GSK announced data have been received from Phase III Harmony 8 study of cardiovascular safety conducted across the albiglutide programme.
-
GlaxoSmithKline concludes previously announced agreement in principle to resolve multiple investigations with US Government and numerous states
GSKannounced it has reached an agreement with the US Government, to conclude the Companys ongoing Federal government investigations.
-
GSK sets 20 July for expiration of tender offer to acquire Human Genome Sciences
GSK announced it has extended its tender offer to acquire all of the outstanding shares of HGSI for US$13.00 per share 5pm NY 20/07/12
-
GSK continues with tender offer to acquire all outstanding shares of Human Genome Sciences
GSK confirmed receiving an invitation from HGS to participate in its strategic alternatives review process which started in April.
-
GSK receives FDA approval for MenHibrix
GSK plc announced today that the US FDA has approved the vaccine MenHibrix, Haemophilus b Tetanus Toxoid Conjugate Vaccine].
-
Stiefel signs worldwide acquisition and license agreement for Toctino®
Stiefel announced it has entered into a worldwide agreement to acquire Toctino (alitretinoin) from Basilea Pharmaceutica Ltd. (Basilea).
-
GSK announces new 52-week data from phase III study of once-weekly albiglutide in type 2 diabetes
Phase III study comparing albiglutide to Lispro, were presented today at the ADA Meeting in Philadelphia, USA.
-
GSK extends tender offer for all outstanding shares of Human Genome Sciences
GSK announced it has extended its tender offer to acquire all of the outstanding shares of HGS for US$13.00 per share 5:00pm NY 29/06/12
-
GSK and XenoPort receive FDA approval for Horizant® for postherpetic neuralgia
GSK & XNPT announced today that the FDA has approved Horizant, Extended-Release Tablets for the management of PHN in adults.
-
GSK announces expiration of Hart-Scott-Rodino waiting period for tender offer for HGS
GSK announced that the waiting period under the HSR Act, has expired with respect to GSK tender offer for all the outstanding shares of HGS
-
GSK and EPSRC announce creation of new Chair in Sustainable Chemistry at the University of Nottingham
GSK & EPSRC announced they will contribute to funding for a Chair in Sustainable Chemistry to be based at GSK's Carbon Neutral Laboratory
-
Regulatory Update – GSK announces submissions in the EU & US for new indications for Promacta®/Revolade®
GSK's submitted regulatory applications in the EU and US related to eltrombopag to increase platelet counts in patients with chronic hep C
